—
C+
C+ The full Closelook — membership. Open the C+ overview

Biomarin Pharmaceutical Inc (BMRN) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Biomarin Pharmaceutical Inc

BMRN in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
BioMarin develops and sells enzyme-replacement and other therapies for rare genetic diseases, including VIMIZIM, NAGLAZYME, PALYNZIQ, BRINEURA and ALDURAZYME, plus VOXZOGO for achondroplasia and KUVAN for phenylketonuria. It also runs an early pipeline that includes BMN 333, a longer-acting growth-disorder candidate, and BMN 351 for Duchenne muscular dystrophy. It sells through specialty pharmacies, hospitals and distributors worldwide and is based in San Rafael, California.
Where it sits in the stack
BioMarin carries no seat in our Rubin AI build-out index; it sits instead in the healthcare sleeve of our universe, in the biotechnology industry, outside any layer of the chip or data-centre stack the diary otherwise tracks.
Who it is priced against
The diary holds no peer group for BioMarin in this record; the market's usual comparison is with Alexion, another rare-disease biotechnology name built around enzyme and antibody therapies.
Why Closelook tracks it
It is a Russell 1000 constituent; it does not carry a Closelook score yet, and the diary has not quoted or featured it in an edition so far.
What the diary watches
Whether pipeline readouts on BMN 333 and BMN 351 advance, and whether analyst price targets keep drifting from their recent level as the chart sits off its high.

Biomarin Pharmaceutical Inc (BMRN) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for BMRN, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 7 analyst actions on the wire · latest: price target by BMO Capital, 2026-09-15

The Street on this name

Analyst actions and the latest print for BMRN from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target BMO Capital — target 97 from 98 Target cut to $97 from $98 (+50.2% to spot) 2026-09-15
  • Price target Cantor Fitzgerald — target 86 from 85 Target raised to $86 from $85 (+31.7% to spot) 2026-09-01
  • Price target Piper Sandler — target 90 from 88 Target raised to $90 from $88 (+38% to spot) 2026-09-01

7 actions on the analyst wire since 2026-08-13: 7 target changes. Analyst wire → · Earnings wire →

Who it is priced against Biotechnology · United States · 8 names with week and year-to-date

Peer group

Biotechnology · United States

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against BMRN on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Biomarin Pharmaceutical Inc (BMRN)?

Biomarin Pharmaceutical Inc trades as BMRN on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-19.

Is BMRN in a Closelook index?

Not currently — Biomarin Pharmaceutical Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does BMRN trade against its moving averages?

Uptrend stack intact: Trades +0.4% vs the 50-day and +9.6% vs the 200-day average, 9.9% below the 52-week high and +29.8% off the 52-week low; a golden cross printed 42 sessions ago. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Biomarin Pharmaceutical Inc do?

BioMarin develops and sells enzyme-replacement and other therapies for rare genetic diseases, including VIMIZIM, NAGLAZYME, PALYNZIQ, BRINEURA and ALDURAZYME, plus VOXZOGO for achondroplasia and KUVAN for phenylketonuria. It also runs an early pipeline that includes BMN 333, a longer-acting growth-disorder candidate, and BMN 351 for Duchenne muscular dystrophy. It sells through specialty pharmacies, hospitals and distributors worldwide and is based in San Rafael, California. The diary holds no peer group for BioMarin in this record; the market's usual comparison is with Alexion, another rare-disease biotechnology name built around enzyme and antibody therapies.

Where does Biomarin Pharmaceutical Inc sit in the AI build-out?

BioMarin carries no seat in our Rubin AI build-out index; it sits instead in the healthcare sleeve of our universe, in the biotechnology industry, outside any layer of the chip or data-centre stack the diary otherwise tracks. It is a Russell 1000 constituent; it does not carry a Closelook score yet, and the diary has not quoted or featured it in an edition so far.

What has Wall Street done on Biomarin Pharmaceutical Inc recently?

The most recent analyst action on Biomarin Pharmaceutical Inc on the Closelook wire is a price target by BMO Capital on 2026-09-15 (target 97 from 98). 7 actions on the analyst wire since 2026-08-13: 7 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for BMRN, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.